{ "Imaging for Metastatic Non-Small Cell Lung Cancer with Brain Metastases", "This study is looking at a new imaging agent called fluorine-18-AlphaVBeta6-BP (\[18F\]-αvβ6-BP) to see how well it can detect non-small cell lung cancer (NSCLC) that has spread, especially to the brain. Researchers believe this new imaging method, when used with a PET/CT scan, could be a sensitive way to assess the disease. You might be able to join if you are over 18, have NSCLC with brain metastases, and are expected to live at least 3 months. The study aims to see how accurate this new imaging agent is compared to standard methods. The current status of the study is unclear, and it plans to enroll 20 participants.", "design": "This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 20 participants.", "commitments": "You would receive two injections of \[18F\]-αvβ6-BP for PET/CT scans at baseline and again 8-12 weeks later. You will also have standard-of-care imaging like FDG PET/CT and brain MRI.", "compensation": "Not stated in the trial record.", "follow_up": "The primary endpoint, comparing imaging to tissue samples, is measured up to six months." }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.